Related Experiment Video

Updated: Jun 5, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR

Roberto Gedaly1, Paul Angulo, Jonathan Hundley

  • 1Department of Surgery, University of Kentucky, College of Medicine, Lexington, KY 40536, USA. rgeda2@uky.edu

Anticancer Research
|December 29, 2010
PubMed
Abstract

Insights

Sorafenib and PI-103 synergistically inhibit hepatocellular carcinoma (HCC) cell proliferation by blocking key Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. This combination therapy offers a promising strategy for HCC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrant signaling in Ras/Raf/MAPK and PI3K/AKT/mTOR pathways is implicated in hepatocellular carcinoma (HCC).
  • Sorafenib, a multi-kinase inhibitor, and PI-103, a dual PI3K/mTOR inhibitor, are investigated for their effects on HCC progression.

Purpose of the Study:

  • To evaluate the efficacy of sorafenib and PI-103, alone and in combination, in inhibiting the proliferation of the Huh7 HCC cell line.
  • To elucidate the molecular mechanisms underlying the anti-proliferative effects of these inhibitors on key signaling pathways.

Main Methods:

  • Huh7 cell proliferation was assessed using 3H-thymidine incorporation and MTT assays.
  • Western blot analysis was employed to detect the phosphorylation status of critical enzymes in the Ras/Raf and PI3K signaling cascades.
  • The impact of sorafenib and PI-103 on epidermal growth factor (EGF)-stimulated signaling was investigated.

Main Results:

  • Both sorafenib and PI-103 demonstrated dose-dependent inhibition of Huh7 proliferation, with synergistic effects observed upon combination.
  • Sorafenib inhibited EGF-induced MEK and ERK phosphorylation, while PI-103 suppressed EGF-stimulated PI3K/AKT/mTOR pathway activation.
  • The combination of sorafenib and PI-103 resulted in the simultaneous inhibition of all tested kinases within both the Ras/Raf and PI3K pathways.

Conclusions:

  • The combination of sorafenib and PI-103 effectively inhibits EGF-stimulated Huh7 cell proliferation.
  • This synergistic effect is achieved through the concurrent blockade of both the Ras/Raf/MAPK and PI3K/AKT/mTOR signaling pathways.
  • Combined sorafenib and PI-103 treatment presents a potent therapeutic strategy for hepatocellular carcinoma.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...